Selected Grants
Prospective Randomized Evaluation and Management of Premature Atherosclerosis
Clinical TrialPrincipal Investigator · Awarded by DCRI-Duke-Site · 2026 - 2032A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established ASCVD or at High Risk for a FIRST ASCVD Event
Clinical TrialPrincipal Investigator · Awarded by AstraZeneca Pharmaceuticals, LP · 2026 - 2032A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants with Elevated Lipoprotein(a)
Clinical TrialPrincipal Investigator · Awarded by Amgen, Inc. · 2026 - 2032MK-0616
Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme LLC. · 2024 - 2030A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a) OCEAN(a)-Outcomes- Olpasiran trials
Clinical TrialPrincipal Investigator · Awarded by Amgen, Inc. · 2023 - 2028A Placebo-Controlled, Double-Blind, Randomized,Phase3 Study to Evaluate the Effect of Obicetrapib 10 mg and Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants
Clinical TrialPrincipal Investigator · Awarded by NewAmsterdam Pharma B.V. · 2026 - 2028Bending the Cardiovascular Curve: Health-system Intervention to Improve Disparities in Lipid Management
ResearchPrincipal Investigator · Awarded by NewAmsterdam Pharma B.V. · 2026 - 2028V-INCLUSION
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2024 - 2027Test to Treat: A Randomized Implementation Trial to Improve LDL-C Management after Hospitalization for ASCVD
Clinical TrialPrincipal Investigator · Awarded by Amgen, Inc. · 2024 - 2027The impact of Abnormal Lipid Panel Result Flagging
ResearchPrincipal Investigator · Awarded by Amgen, Inc. · 2026 - 2026Biomarkers in Acute Severe Hypertension (ASH): Analysis of Clinical Blood Samples from patients presenting to the ED and/or admitted with a diagnosis of Acute Severe Hypertension or recorded SBP ¿ 180 mmHg.
Clinical TrialPrincipal Investigator · Awarded by Kardigan Inc. · 2025 - 2026Study of the Prevalence of Endogenous Hypercortisolism in Patients with Resistant Hypertension (MOMENTUM)
Clinical TrialPrincipal Investigator · Awarded by Corcept Therapeutics, Inc. · 2025 - 2026SEER-CV Registry (EFFECTIVENESS OF PCSK9I IN THE PREVENTION OF CARDIOVASCULAR DISEASE: A GLOBAL REGISTRY REAL WORLD DATA IN PATIENTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE)
Clinical TrialPrincipal Investigator · Awarded by Amgen, Inc. · 2021 - 2026Optimizing the Management and Outcomes for Cancer Survivors Transitioning to Follow-up Care
ResearchCo Investigator · Awarded by National Cancer Institute · 2020 - 2026A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Zilebesiran Used as Add-on Therapy in Adult Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care
Clinical TrialPrincipal Investigator · Awarded by Alnylam Pharmaceuticals · 2024 - 2026Lorundrostat in Uncontrolled HTN
Clinical TrialPrincipal Investigator · Awarded by Mineralys Therapeutics, LLC · 2023 - 2025REVEAL
ResearchPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2022 - 2024Creating the Learning Healthcare Platform of the Future: High Risk ASCVD Registry for Longitudinal follow up
ResearchPrincipal Investigator · Awarded by Janssen Scientific Affairs, LLC. · 2018 - 2024A Cross-sectional Study of Lipoprotein(a) Levels in Patients With Documented History of ASCVD
Clinical TrialPrincipal Investigator · Awarded by Amgen, Inc. · 2022 - 2023External Relationships
- Amarin
- American Heart Journal
- Amgen, Inc.
- Novartis pharmaceuticals
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.